Jiang Wenbin 4
4 · Cytek Biosciences, Inc. · Filed Mar 12, 2026
Research Summary
AI-generated summary of this filing
Cytek (CTKB) CEO Jiang Wenbin Receives RSUs and Exercises/Converts Derivatives
What Happened
Jiang Wenbin, President & CEO and a director of Cytek Biosciences (CTKB), had multiple equity events reported for March 10, 2026. He was granted/awarded two RSU awards totaling 1,400,952 RSU units (485,545 and 915,407 RSUs). In addition, three derivative exercises/conversions occurred for 15,708; 29,467; and 38,669 shares (total = 83,844). To satisfy tax withholding obligations arising from vesting/conversion, 20,988 shares were withheld/surrendered to the company at $4.23 per share, totaling $88,780. No open‑market sale proceeds to Jiang are reported — the only disposals reflect shares withheld for taxes or conversion mechanics.
Key Details
- Transaction date: March 10, 2026; Form 4 filed March 12, 2026 (timely).
- Awards granted: 485,545 RSUs and 915,407 RSUs (total 1,400,952 RSUs) recorded as acquisitions (derivative awards) at $0.00.
- Derivative exercises/conversions: 15,708; 29,467; and 38,669 shares (total 83,844). Some conversion entries are recorded as disposals at $0.00, reflecting conversion/transfer rather than a market sale.
- Tax withholding: 3,825 + 7,747 + 9,416 = 20,988 shares surrendered to issuer to cover withholding, at $4.23/share = $88,780. (Transaction code F = tax/exercise payment.)
- Vesting notes: awards vest over four years under multiple schedules (see footnotes F3–F7); some awards include vesting events on March 10, 2026.
- Shares owned after transaction: not specified in the information provided.
Context and plain English explanation:
- These filings show RSU grants and the conversion/vesting of derivative awards, not open‑market purchases or sales. RSUs convert to common stock when they vest (no cash purchase required); the company commonly withholds some shares to cover taxes (the withheld shares are the only shares shown as “disposed”).
- Transaction codes: A = award/grant, M = exercise/conversion of derivative, F = payment of exercise price or tax withholding.
- This activity is routine compensation/vesting and does not necessarily indicate insider sentiment for open‑market buying or selling.
Insider Transaction Report
Form 4
Jiang Wenbin
DirectorPRESIDENT AND CEO
Transactions
- Exercise/Conversion
Common Stock
[F1]2026-03-10+15,708→ 5,375,535 total - Tax Payment
Common Stock
[F2]2026-03-10$4.23/sh−3,825$16,180→ 5,371,710 total - Exercise/Conversion
Common Stock
[F1]2026-03-10+29,467→ 5,401,177 total - Tax Payment
Common Stock
[F2]2026-03-10$4.23/sh−7,747$32,770→ 5,393,430 total - Exercise/Conversion
Common Stock
[F1]2026-03-10+38,669→ 5,432,099 total - Tax Payment
Common Stock
[F2]2026-03-10$4.23/sh−9,416$39,830→ 5,422,683 total - Award
Employee Stock Option (right to buy)
[F3]2026-03-10+485,545→ 485,545 totalExercise: $4.23Exp: 2036-03-09→ Common Stock (485,545 underlying) - Award
Restricted Stock Units
[F1][F4]2026-03-10+915,407→ 915,407 total→ Common Stock (915,407 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F5]2026-03-10−15,708→ 47,129 total→ Common Stock (15,708 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F6]2026-03-10−29,467→ 176,806 total→ Common Stock (29,467 underlying) - Exercise/Conversion
Restricted Stock Units
[F1][F7]2026-03-10−38,669→ 348,030 total→ Common Stock (38,669 underlying)
Footnotes (7)
- [F1]Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
- [F2]Represents the number of shares withheld by and surrendered to the Issuer on March 10, 2026, to satisfy tax withholding obligations that arose in connection with the vesting of the RSU Award.
- [F3]The shares subject to the stock option shall vest over 4 years with 1/48 of the total shares underlying the stock option vesting on April 10, 2026 and each month thereafter until fully vested.
- [F4]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2026 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting August 18, 2026 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting November 18, 2026 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2027 and each March 10 thereafter, until fully vested.
- [F5]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2023 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2023 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2023 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2024 and each March 10 thereafter, until fully vested.
- [F6]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2024 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2024 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2024 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2025 and each March 10 thereafter.
- [F7]The shares subject to the RSU Award shall vest over 4 years with 2/48 of the total shares underlying the RSU Award vesting on May 18, 2025 and each May 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on August 18, 2025 and each August 18 thereafter; 3/48 of the total shares underlying the RSU Award vesting on November 18, 2025 and each November 18 thereafter; and 4/48 of the total shares underlying the RSU Award vesting on March 10, 2026 and each March 10 thereafter, until fully vested.
Signature
/s/ Valerie Barnett, Attorney-in-Fact|2026-03-12